Cytori Stem & Regenerative Cell Heart Attack Trial Feasible & Safe
"Cytori is very optimistic based on all of the data we have seen in this trial," said Marc H. Hedrick, M.D., president, Cytori Therapeutics. "The Company met its goals for the trial after finishing the first cohort of 12 patients. Most importantly, we needed to show that the fat harvest could be done safely on sick heart attack patients and that we could re-deliver the stem and regenerative cells back to these patients through the coronary artery in the same surgical procedure early in the peri-myocardial infarction period. In my view, this result is a major accomplishment for Cytori and the regenerative medicine field."
The APOLLO trial is a prospective, double blind, placebo controlled, safety and feasibility study. It was designed to investigate up to four doses of cells consisting of 12 patients per each dose, with three patients receiving stem and regenerative cells to every one patient receiving placebo in each cohort. Assessments and observations made by the principal investors and DSMB factored into Cytori's decision to complete enrollment after the first dose cohort and begin designing and seeking approvals to initiate a European pivotal study at this dose. Cytori is presently in discussion with its notified body in Europe to negotiate study size needed to show efficacy and achieve reimbursement.
At the recent 6th International Conference on Cell Therapy for Cardiovascular Disease hosted in January 2009, Dr. Patrick Serruys, principal investigator for APOLLO, presented encouraging six month outcome data on the subset of cohort one patients, which had been evaluated thus far. Although Cytori remains blinded to treatment versus control, evaluation of this data was considered by both Cytori and the investigators in the determination to proceed to a pivotal trial.
Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc. manufactures, develops, and internationally commercializes innovative medical technologies, which allow physicians to practice regenerative medicine. Commercial activities are currently focused on marketing the Celution(R) cell processing system and related family of products across three areas. The first is Cosmetic and reconstructive surgery in Europe and Asia-Pacific. The second is to fulfill the demand among physicians in Europe and Asia Pacific for access to clinical grade stem and regenerative cells. The third is to market the Celution-based StemSource(R) Cell Bank worldwide to hospitals and tissue banks so they can in turn offer patients the opportunity to cryopreserve their own adipose-derive stem and regenerative cells. The company's development pipeline includes applications for cardiovascular disease, renal failure, orthopedic damage, gastrointestinal disorders, and pelvic health conditions, among others. www.cytoritx.com